Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in castration-resistant prostate cancer metastatic to the bone (mCRPC).

被引：0
|
作者：
Snedecor, S. J.
Carter, J. A.
Kaura, S.
Botteman, M.
机构：
[1] Pharmerit North Amer, Bethesda, MD USA
[2] Nova Pharmaceut Corp, Oncol Hlth Econ & Outcomes Res, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4581
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?
    L E Howard
    A M De Hoedt
    W J Aronson
    C J Kane
    C L Amling
    M R Cooperberg
    M K Terris
    C H Divers
    A Valderrama
    S J Freedland
    Prostate Cancer and Prostatic Diseases, 2016, 19 : 380 - 384
  • [32] ECONOMIC EVALUATION OF DENOSUMAB VERSUS ZOLEDRONIC ACID (ZA) IN THE PREVENTION OF SKELETAL-RELATED EVENTS (SRE) IN PATIENTS WITH PROSTATE CANCER WITH BONE METASTASIS (BM) IN MEXICO
    Arocho, R.
    Rivera Hurtado, R.
    Carlos, F.
    VALUE IN HEALTH, 2013, 16 (03) : A139 - A140
  • [33] ZOLEDRONIC ACID IS COST EFFECTIVE FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH PROSTATE CANCER AND BONE METASTASES IN FRANCE AND GERMANY
    Meijboom, Marjan
    Botteman, Marc F.
    Kaura, Satyin
    JOURNAL OF UROLOGY, 2009, 181 (04): : 295 - 295
  • [34] Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States
    Stopeck, Alison
    Brufsky, Adam
    Kennedy, Lisa
    Bhatta, Sumi
    Bhowmik, Debajyoti
    Buchanan, Jacqueline
    Despiegel, Nicolas
    Hechmati, Guy
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (01) : 37 - 47
  • [35] SKELETAL-RELATED EVENTS (SRES) IMPACT SIGNIFICANTLY THE HEALTH-RELATED QUALITY OF LIFE (HRQOL) OF CHEMO-NAIVE MEN WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
    Ivanescu, C.
    Phung, D.
    Loriot, Y.
    Saad, F.
    Mansbach, H.
    Beer, T. M.
    Tombal, B.
    Holmstrom, S.
    VALUE IN HEALTH, 2014, 17 (07) : A650 - A651
  • [36] A COMPARISON OF THE COST-EFFECTIVENESS OF ZOLEDRONIC ACID FOR PREVENTING SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES FROM PROSTATE CANCER IN 4 EUROPEAN COUNTRIES
    Botteman, M.
    Carter, J.
    Kaura, S.
    VALUE IN HEALTH, 2010, 13 (07) : A264 - A264
  • [37] Costs of skeletal-related events (SREs) in patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with oral therapies.
    Engel-Nitz, Nicole
    Behl, Ajay S.
    Blauer-Peterson, Cori
    Li, Sophia S.
    Dawson, Nancy Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [38] COST EFFECTIVENESS OF ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL RELATED EVENTS IN PROSTATE CANCER PATIENTS WITH BONE METASTASES IN FRANCE
    Meijboom, M.
    Botteman, M.
    Kaura, S.
    Durand-Zaleski, I.
    ANNALS OF ONCOLOGY, 2008, 19 : 201 - 201
  • [39] THE BURDEN OF SKELETAL-RELATED EVENTS ON PAIN OUTCOMES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER
    Patrick, Donald
    Smith, Matthew R.
    Fizazi, Karim
    Cleeland, Charles S.
    Fallowfield, Lesley
    Chi, Kim N.
    Wei, Rachel
    Ohrling, Katarina
    Qian, Yi
    JOURNAL OF UROLOGY, 2014, 191 (04): : E920 - E920
  • [40] Examining skeletal-related events in Australian men with castration-resistant prostate cancer (CRPC)
    Anton, A.
    Wong, S.
    Parente, P.
    Azad, A.
    Shapiro, J. A.
    Weickhardt, A.
    Torres, J.
    Parnis, F.
    Goh, J.
    Semira, C.
    Gibbs, P.
    Tran, B.
    Pezaro, C.
    ANNALS OF ONCOLOGY, 2018, 29 : 70 - 70
12345